OncoMatch/Clinical Trials/NCT04176718
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Is NCT04176718 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Daratumumab and Carfilzomib for multiple myeloma.
Treatment: Daratumumab · Carfilzomib · Pomalidomide · Dexamethasone — This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or previous treatment resistant Multiple Myeloma. This research study involves two study drugs and two standard of care drugs. * The names of the study drugs involved in this study are: * Carfilzomib * Daratumumab * The names of the standard of care drugs involved in this study are: * Dexamethasone * Pomalidomide
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Prior therapy
Must have received: immunomodulatory drug (lenalidomide)
Prior therapy must include at least 2 cycles of lenalidomide
Must have received: proteasome inhibitor
at least 2 cycles of a proteasome inhibitor (either in separate regimens or within the same regimen)
Cannot have received: carfilzomib, pomalidomide, and dexamethasone (combination) (carfilzomib, pomalidomide, dexamethasone)
Last line of therapy with the combination of carfilzomib, pomalidomide, and dexamethasone
Cannot have received: chemotherapy
chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study registration
Cannot have received: radiotherapy
chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study registration
Cannot have received: investigational agent
receiving any other investigational agents
Lab requirements
Blood counts
ANC ≥ 1000/μL (G-CSF not permitted within 14 days of screening; exceptions possible with PI approval); Platelet count ≥ 50,000/μL (no platelet transfusion within 7 days of screening); Hemoglobin ≥ 8 g/dL (RBC transfusions permitted)
Kidney function
Calculated creatinine clearance of ≥ 30 mL/min by Cockcroft-Gault equation
Liver function
Serum bilirubin < 2 mg/dL (Gilbert's syndrome exception: total bilirubin <3 mg/dL and normal direct bilirubin); ALT and/or AST < 2.5 × ULN
ANC ≥ 1000/μL. Platelet count ≥ 50,000/μL. Hemoglobin ≥ 8 g/dL. Calculated creatinine clearance of ≥ 30 mL/min by Cockcroft-Gault equation. Serum bilirubin < 2 mg/dL; ALT and/or AST < 2.5 × ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify